Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Serplulimab, Lenvatinib, and Paclitaxel in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After First-line Immunotherapy: a Prospective, Single-armed Clinical Trial

NCT05585580 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.

NCT NCT05585580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05585580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Serplulimab, Lenvatinib, and Paclitaxel in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After First-line Immunotherapy: a Prospective, Single-armed Clinical Trial
Lead sponsor
Qilu Hospital of Shandong University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 1, 2023
Completion date
November 1, 2026
Enrollment
59 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric or gastroesophageal junction adenocarcinoma